​ASDERA

ASDERA develops drugs for unmet needs by utilizing a patented (US Pat. 7,664,616 ) computational biostatistics platform  to identify complex genetic risk factors in small (n>500) epidemiological and phase 2/3 studies.

http://www.asdera.com/
​

Brainstorm Cell Therapeutics, Inc. - ​[NASDAQ:BCLI]

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease and Motor Neuron Disease), Multiple Sclerosis, Parkinson’s Disease, Huntington’s Disease.
Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.

http://www.brainstorm-cell.com/

​Cantabio Pharmaceuticals, Inc.

​Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

http://www.cantabio.com/
​

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing novel treatments for to potentially treat a range of addictions located in the greater Boston, MA area. Embera is developing the first medication that treats addiction by moderating activity in the stress response system.

http://emberaneuro.com/

EryDel SpA

EryDel S.p.A. is a Drug Delivery Company specialized in the development of drugs and diagnostics delivered through human red blood cells via a proprietary medical device technology.

http://www.erydel.com/

Exscientia Ltd.

Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

https://www.exscientia.co.uk/
​

KemPharm, Inc. - ​[NASDAQ: KMPH]

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.

http://www.kempharm.com/

K-PAX Pharmaceuticals, Inc.

KPAX002, our patented compound, is an enhanced, CNS stimulant, bolstered by our proprietary mitochondrial technology, now possessing the ability to treat fatigue in patients with neurodegenerative diseases.  We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy. Fatigue in neurodegenerative disorders represents a serious unmet medical need.  

​We are concurrently pursuing several indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease cognitive symptoms 3) Myalgic encephalomyelitis/CFS

http://www.kpaxpharmaceuticals.com/
​

M3 Biotechnology, Inc.

M3 Biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. The lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. The company’s research has been funded by the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, W Fund, WRF Capital, Dolby Family Ventures and other private investors.

http://m3bio.com/
​

Minoryx Therapeutics S.L.

Minoryx is a drug development company specializing in the discovery of new drugs for orphan diseases. The company targets Inborn Errors of Metabolism; a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program is a differentiated PPAR gamma agonist (MIN-102) that has multiple CNS indications. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurologic deterioration with no available pharmacological treatment. Minoryx is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – SEE-Tx. 

http://www.minoryx.com/

NeuroRx, Inc.

NeuroRx, Inc. is a clinical stage pharmaceutical company that is developing Cyclurad™, the first oral therapeutic for the treatment of suicidal crisis associated with bipolar disorder. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. 

http://www.neurorxpharma.com/

Neurotrope BioScience, Inc. - ​[OTCQB:NTRP]

Neurotrope BioScience, (OTCQB:NTRP), formed in 2012, is at the forefront of the biotech industry and is focused on developing new therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders.
Our experience, capabilities, and passion for innovative and novel drug therapies have enabled us to build a development pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat diseases such as Alzheimer’s dementia and the Orphan diseases, Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC).

http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/index.html
​

​Nexeon Medsystems, Inc.

​Nexeon Medsystems, Inc. is a global medical device company focused on providing innovative neurostimulation products that improve the quality of life of patients suffering from debilitating neurological disease.  Nexeon has developed and commercialized the Synapse™ neurostimulation system, an adaptive, closed-loop platform that can be utilized to treat a variety of neurological diseases.  

https://www.nexeonmed.com/
​

Oryzon Genomics SA - [BME:ORY]​

Oryzon is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics. With one compound in Phase I/IIA in oncology, ORY-1001, a highly potent LSD1 inhibitor with exquisite selectivity that has been granted orphan-drug status by the EMA, a second compound expected to enter in clinical development in 2016 for Alzheimer's Disease and additional programs in other cancer indications, the company has a broad and growing portfolio. Oryzon was founded in 2000 by Tamara Maes and Carlos Buesa. The company is headquartered in Barcelona, Spain with 30 employees, and is considered the biopharmaceutical company of reference in Spain. From its founding through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases, with a focus on Alzheimer’s disease and hematological cancers. Our business model is to develop our proprietary drug candidates through clinical phase II.

The company has a seasoned executive management with vast experience in the industry.

Our lead oncology program was licensed in 2014 to Roche in a collaboration transaction valued at over $500 million.

https://www.oryzon.com/

Pharmasum Therapeutics AS

Pharmasum Therapeutics is a private, Norwegian pharmaceutical company focused on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The Company shall develop drugs to at least Proof-of-Concept stage, but will be seeking strategic partnerships with larger pharmaceutical companies potentially for early-stage collaborations, late-stage development and marketing. The preferred deal-structure takes form as a co-development partnership, where Pharmasum may reserve rights to marketing and co-promotion in certain territories. The Company shall also be open to non-organic growth through M&A processes.

http://www.pharmasum.com/

Probiodrug AG - ​[AMS:PBD] 

Probiodrug AG is a biopharmaceutical company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients. Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are  targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.

http://www.probiodrug.de/

​ProMIS™ Neurosciences, Inc. - ​[TSE:PMN] 

Traded on the Toronto Stock Exchange (TSX), under the symbol PMN, ProMIS™ Neurosciences, Inc., is a development stage biotech company that discovers and develops game changing precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

http://promisneurosciences.com/
​

​Purdue Pharma L.P.

Purdue Pharma, a private company founded by physicians, is committed to advancing the medical care of patients with quality pharmaceutical products. We are known for our pioneering research in pain, a principal cause of human suffering. Today, we work with new partners on innovative healthcare solutions in many therapeutic areas.

http://www.purduepharma.com/

​SalubRX Therapeutics, Inc.

SalubRx Therapeutics Inc. is a privately owned semi-virtual pharmaceutical company developing new chemical entities (NCEs) for the treatment of neurological disorders. SalubRx Therapeutics Inc. has developed a platform of selective inhibitors of the nitric oxide synthase (NOS) enzyme family, the enzyme which produces nitric oxide (NO). As the first company to be able to specifically target and inhibit the individual isozymes (nNOS, eNOS, iNOS), SalubRx can avoid any of the effects of blood pressure usually associated with eNOS providing the benefits of nNOS and iNOS alone or in combination as required. NO has been implicated in a wide variety of neurological disorders from migraine through to neurodegeneration. SalubRx’s selective NOS inhibitors may be especially suited to neurodegenerative diseases as a transformative symptomatic and disease modifying treatment. Parkinson’s Disease (PD) in particular may be particularly amenable to NOS based therapeutics.

http://www.salubrx.com/

Quartet Medicine

Quartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet is capitalizing on these insights by safely restoring BH4 homeostasis in neuronal and inflammatory cells.
​
Quartet was founded by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland in conjunction with Atlas Venture. Quartet’s Series A investors include Atlas Venture, Novartis Venture Funds, Pfizer Venture Investments and Partners Innovation Fund. The company is based in Cambridge, Massachusetts and has research efforts underway with collaborators in the US, Europe and Asia.

https://quartetmedicine.com/

​SunRegen Healthcare AG

SunRegen Healthcare AG is a start-up company in novel neurological drug development in Basel Area in Switzerland. We have successfully discovered a key active ingredient (a compound) from Chinese medicinal herb for the treatment of neurodegenerative diseases. The compound has demonstrated potent neuroprotective, neurorescue and potential neuroregenerative effects. We aim to obtain HA approval of our product as an orphan drug as early as 2020.

​T3D Therapeutics, Inc.

A Transformational Approach to Treating Alzheimer’s Disease … and more.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease, a drug with the potential to slow, stop or reverse the course of the disease.

​http://www.t3dtherapeutics.com/

vasopharm GmbH

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences – indications with significant unmet clinical need. The company is focused on the development of therapeutics which steer the availability of biological nitric oxide (NO) over the entire NO signal cascade and its functional counterpart the NAD(P)H oxidase (NOX) family.

http://www.vasopharm.com/
​